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The purpose of this study is to evaluate in vitro gene delivery mediated by asialofetuin-appended cationic liposomes (AF-
liposomes) associating cyclodextrins (CyD/AF-liposomes) as a hepatocyte-selective nonviral vector. Of various CyDs, AF-
liposomes associated with plasmid DNA (pDNA) and γ-cyclodextrin (γ-CyD) (pDNA/γ-CyD/AF-liposomes) showed the highest
gene transfer activity in HepG2 cells without any signiﬁcant cytotoxicity. In addition, γ-CyD enhanced the encapsulation ratio
of pDNA with AF-liposomes, and also increased gene transfer activity as the entrapment ratio of pDNA into AF-liposomes was
increased. γ-CyD stabilized the liposomal membrane of AF-liposomes and inhibited the release of calcein from AF-liposomes. The
stabilizing eﬀect of γ-CyD may be, at least in part, involved in the enhancing gene transfer activity of pDNA/γ-CyD/AF-liposomes.
Therefore, these results suggest the potential use of γ-CyD for an enhancer of transfection eﬃciency of AF-liposomes.
1.Introduction
The principle of somatic gene therapy is that genes can be
introduced into selected cells in the body in order to treat
genetic or acquired diseases. The liver may be potentially an
important target for gene therapy, because crucial diseases
such as amyloidosis, primary biliary cirrhosis, familial
hypercholesteremia, phenyl ketonuria, and virus hepatitis
occur in this organ [1]. In addition, the liver has the ability
to synthesize a wide variety of proteins, to perform various
posttranslational modiﬁcations, and to secrete them into the
blood.
Of various nonviral methods, the lipofection method,
by which cationic lipids (cationic liposomes) are used for
transfection and interact with plasmid DNA (pDNA) to
give a lipoplex, has recently attracted attention [2]. Cationic
liposomes have great advantages as gene delivery carriers
such as (1) low cytotoxicity and immunogenicity [3], (2)
regulationofthepharmacokineticsthroughthemodiﬁcation
of particle size or lipids components of liposomes [4], (3)
entrapment of pDNA into inner water phase of liposomes
and suppression of DNA degradation by DNase [5], and (4)
deliveryofgenetotargetcellsbytheadditionoftargetligands
and/or antibody [6].
Asialofetuin (AF) is a glycoprotein that possesses three
asparagine-linkedtriantennarycomplexcarbohydratechains
with terminal N-acetylgalactosamine residues. The protein
displays aﬃnity to asialoglycoprotein receptor (ASGP-R) on
hepatocytes and enters the cells through the receptor [7, 8].
Thus, AF has been used as a ligand to deliver drugs to
hepatocytes and a competitive inhibitor to ASGP-R [9, 10].
In fact, the widespread use of AF-appended liposomes (AF-
liposomes) as a hepatocyte-selective gene transfer carrier has
been reported [11, 12].
Cyclodextrins (CyDs) have recently been applied to gene
transfer and oligonucleotide delivery [13–16]. CyDs are2 Journal of Drug Delivery
cyclic (α-1,4)-linked oligosaccharides of α-D-glucopyranose
containing a hydrophobic central cavity and hydrophilic
outer surface, and they are known to be able to act as
novel host molecules by chemical modiﬁcation [17]. Davis
and his colleagues reported that the ternary complex of
a water-soluble β-CyD polymer with 6A,6D-dideoxy-6A,-
6D-di-(2-aminoethanethio)-β-CyD and dimethylsuberimi-
date (βCDP6), galactosylated, or transferrin polyethylene
glycol conjugates with adamantane, and pDNA possesses
higher transfection eﬃciency in hepatoma or leukemia
cells, respectively, through receptor-mediated endocyto-
sis [18, 19]. Recently, we reported the potential use of
PAMAM dendrimer functionalized with α-CyD (α-CDE)
[20]a n dl a c t o s y l a t e dα-CDE (Lac-α-CDE) as a hepatocyte
speciﬁc gene delivery in vitro and in vivo [21]. Mean-
while, Lawrencia et al. reported that lipoplex transfection
of pDNA with DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-
N,N,N-trimethylammonium methyl-sulfate) in the presence
of cholesterol, which is solubilized by methyl-β-cyclodextrin
(methyl-β-CyD), has signiﬁcantly improved transfection
eﬃciency in urothelial cells due to change in membrane
ﬂuidity by methyl-β-CyD [22]. In addition, we previously
demonstrated that intravenous injection of the pegylated
liposomes entrapping the doxorubicin (DOX) complex with
γ-CyD in BALB/c mice bearing Colon-26 tumor cells
showed DOX accumulation in tumor tissues and the potent
antitumor eﬀect, compared with those of DOX solution
and pegylated liposomes entrapping DOX alone [23]. These
lines of evidence suggest that transfection eﬃciency and
pharmacokinetics of pDNA can be altered by the association
of CyDs with AF-liposomes.
Based on these backgrounds, the purpose of this study is
to evaluate in vitro gene delivery of AF-liposomes associated
with CyDs as a hepatocyte-selective nonviral vector in
HepG2 cells. In addition, the mechanisms by which γ-CyD
enhanced transfection eﬃciency of pDNA/AF-liposomes
were investigated in the view of a receptor recognition,
physicochemical properties (particle size, ζ-potential, and
encapsulation ratio), membrane ﬂuidity, cellularuptake, and
cytotoxicity of AF-liposomes.
2.MaterialsandMethods
2.1. Materials. Dilauroylphosphatidylcholine (DLPC), diol-
eoylphosphatidylethanolamine (DOPE), dipalmitoylphos-
phatidylethanolamine (DPPE), and diacylphosphatidyleth-
anolamine-N-lissamine rhodamine B sulfonyl (RH-PE)
were obtained from Avanti Polar-Lipid (Alabama). N-(α-
Trimethylammonioacetyl)-didodecyl-D-glutamate chloride
(TMAG) was purchased from Sogo Pharmaceutical (Tokyo,
Japan). Asialofetuin (AF) and 2-mercaptoethanol were
obtained from Sigma Chemical (St. Louis, MO). N-
hydroxysulfosuccinimide (Sulfo-NHS) was purchased from
Fluka (Buchs, Switzerland). 1-Ethyl-3-(3-dimethylami-
nopropyl) carbodiimide (EDC) was from Dojindo (Kum-
amoto, Japan). 2-(N-morpholino) ethanesulfonic acid
(MES) and 2-[4-(2-hydroxyethyl)-1-piperazinyl] ethanes-
ulfonic acid (HEPES) were purchased from Nacalai Tesque
Table 1: Chemical structures of CyDs used in this study.
CyDs n RD .S.
(a)
α-CyD 1 H
γ-CyD 3 H
HP-α-CyD(b) 1H o r C H 2CH(CH3)OH 4.0
HP-β-CyD(c) 2H o r C H 2CH(CH3)OH 4.8
HP-γ-CyD(d) 3H o r C H 2CH(CH3)OH 4.3
DM-β-CyD(e) 2H o r C H 3 14
(a) The average degree of substitution, (b) 2-Hydroxypropyl-α-CyD, (c)
2-Hydroxypropyl-β-CyD, (d) 2-Hydroxypropyl-γ-CyD, and (e) 2, 6-Di-O-
methyl-β-CyD.
(Kyoto, Japan). CyDs used in this study were supplied
by Nihon Shokuhin Kako (Tokyo, Japan) (Table 1). The
average degrees of substitution of 2-hydroxypropyl group
in 2-hydroxypropyl-α-CyD (HP-α-CyD), HP-β-CyD, and
HP-γ-CyD are 4.0, 4.8 and 4.3, respectively. Fetal calf serum
(FCS)wasobtainedfromNichirei(Tokyo,Japan).Dulbecco’s
modiﬁed Eagle’s medium (DMEM) was purchased from
Nissui Pharmaceuticals (Tokyo, Japan). Plasmid pRL-CMV-
Luc vector encoding Renilla luciferase and having a CMV
promoter as well as pGL3-control vector encoding ﬁreﬂy
luciferase and having a SV40 promoter were obtained
from Promega (Tokyo, Japan). pEGFP N1 DNA encoding
EGFP and having a CMV promoter was purchased from BD
BioscienceClontech (SanJose,CA). TheseDNAvectorswere
abbreviated to pDNA. The puriﬁcation of pDNA ampliﬁed
in bacteria was carried out using QIAGEN EndoFree
plasmid MAXI kit (<0.1EU/μg endotoxin). Picogreen
dsDNA reagent and ULYSIS Alexa Fluor 488 (Alexa)
Nucleic Acid Labeling Kit were purchased from Molecular
Probes (Tokyo, Japan). Bovine serum albumin (BSA) was
obtained from Roche Diagnostics (Tokyo, Japan). Other
chemicals and solvents were of analytical reagent grade, and
deionized double-distilled water was used throughout the
study.
2.2. Preparation of AF-Liposomes. Preparation of AF-
liposomes was performed according to the method reported
by Hara et al. [11] with some modiﬁcations (Figure 1).
Brieﬂy, lipids mixtures, DLPC/TMAG/DOPE/DPPE
(3/2/4/1, molar ratio, the amount of total lipids was
30μmol), were dissolved in chloroform, and the solvent was
removed under reduced pressure by a rotary evaporator.
After addition of 5mL of 0.1MMES buﬀer (activation
buﬀer, pH 5.0) containing 0.9% NaCl, the solution was
sonicated by a bath type of sonicator (ultrasonic automatic
washer US-4, AS ONE, Osaka, Japan) for 5min under
gassing with nitrogen, and then small unilamellar vesicle,
large unilamellar vesicle, and/or small oligolamellar
liposomes were obtained. Next, 6mg of AF was dissolved
in 1mL of activation buﬀer, which contained 3.3mg of
Sulfo-NHS and 1.2mg of EDC. After mixing for 15min
at room temperature, the reaction was stopped by the
addition of 4.2μL of 2-mercaptothanol and obtained
Sulfo-NHS-AF. Sulfo-NHS-AF was mixed with LUV and
stirred for 2h at room temperature. After addition ofJournal of Drug Delivery 3
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Figure 1: Preparation of asialofetuin-modiﬁed liposomes (AF-
liposomes). (a) Preparation pathway of AF-liposomes. (b) Elution
proﬁles of AF-liposomes determined by gel ﬁltration chromatogra-
phy.
hydroxylamine HCl, AF-liposomes were obtained. To
remove the free AF, we performed gel ﬁltration using
Sepharose CL-4B column (Amersham Pharmacia Biotech,
Freiburg, Germany) and determined phospholipids and
AF by the Bartlett method [24] and the Bradford method
[25], respectively. The fractions number 26–30, which
eluted both phospholipids and AF, were collected as the
AF-liposomes fraction (Figure 1(b)). The ζ-potential value
and particle size of AF-liposomes were 31.2 ± 0.1mV and
230.7±4.2nm, respectively. The amount of AF modiﬁcation
in 1μmol of AF-liposome lipids was 35.8μg/μmol lipids,
indicating that AF modiﬁcation rate against DPPE in
liposomes was 0.75%. Liposomes without AF modiﬁcation
(N-liposomes) was prepared by the solution without Sulfo-
NHS-AF, and the other procedure was the same as that of
AF-liposomes.
2.3. Preparation of pDNA/CyDs/AF-Liposomes. Preparation
of pDNA/CyD/AF-liposomes was performed according to
the method reported by Hara et al. with some modiﬁcations
[12]. Brieﬂy, 2μL of the solution containing pDNA (1μg/μL)
and CyDs (1μM/μM lipids) dissolved in TE buﬀer were
added to AF- or N-liposomes suspension. After mixing, the
solution was freeze-dried. Then, the sample was rehydrated
with THBS (10mM, pH 7.5) for 30min. After freezing-
thawing for three times, the vesicles were extruded through
PVDF membranes (Nucleopore, Plesanton, CA) with pores
of diameter 450 and 200nm. The ﬁltrates were used
for further experiments as pDNA/CyDs/AF-liposomes or
pDNA/CyDs/N-liposomes. The entrapment ratios of CyDs
were evaluated by the anthrone-sulfuric acid method [26].
Brieﬂy, 3mL of anthrone reagent was added to 0.5mL of
the suspension containing CyDs/liposomes. The tube was
c o v e r e dwi t hagl a s sb a l la n dw a sh e a t e df o r1 0m i ni nb o i l i n g
water. After quenching with cold water, absorbance of the
suspension was measured by a U-2000A spectrophotometer
(Hitachi, Tokyo, Japan) at 620nm. The encapsulation ratios
of pDNA were determined by a ﬂuorescent spectrometer F-
4500 (Hitachi, Tokyo, Japan). Brieﬂy, 350μL of the suspen-
sion containing pDNA/CyD/AF-liposomes in 10mM THBS
(pH 7.5) were mixed with 200 times diluted Picogreen
dsDNA reagent (350μL). After incubation for 30min at
25◦C, ﬂuorescent intensity (Fpo) was determined. Next, after
addition of 20% of Triton-X (20μL) to the sample, ﬂuores-
cent intensity (Fpt) was determined and the encapsulation
ratio of pDNA was calculated as follows: encapsulation ratio
(%) = [(Fpt ·r −Fpo)/Fpt ·r]·100, where r is compensation
coeﬃcient (r = 1.0 3 ) .P a r t i c l es i z ea n dζ-potential value
of liposomes in 10mM THBS (pH 7.5) were measured by
a submicron particle analyzer N4 Plus (Beckman Coulter,
Fullerton, CA) and ELS-8000 (Otsuka Electronics, Osaka,
Japan), respectively.
2.4. Interaction of CyDs with AF-Liposomes. AF-liposomes
encapsulating calcein were prepared by the freezing and
thawing method after addition of 0.1mM calcein in 10mM
THBS (pH 7.5). The vesicles were extruded through two
stacked polycarbonate membranes (Nucleopore, Plesanton,
CA) with pores of diameter 1μm. The sample was subjected
to 10 passes through the ﬁlter at 40◦C. The ﬁltrates
were extruded through the polycarbonate membranes (pore
size 0.2μm) as described above. Two milliliters of CyDs
solution adjusted at the appropriate concentration (5–
20mM) using 10mM phosphate buﬀer were added to
20μL of the liposomal suspension, and then the resulting
suspension was incubated for 30min at 25◦C. The ﬂu-
orescence intensity of calcein (Ft) was measured with a
ﬂuorophotometer (Hitachi F-4500, Tokyo, Japan) at 25◦C;
excitation and emission wavelengths were 490 and 520nm,
respectively. After addition of 20μL of cobalt chloride
solution (10mM) to the sample to quench the ﬂuorescence4 Journal of Drug Delivery
of nonencapsulated calcein, the intensity of ﬂuorescence of
encapsulated calcein (Fin) was also determined. Then, the
liposomes were completely disrupted by the addition of
20μL of Triton X-100 (20%) solution, and the intensities
of ﬂuorescence after quenching by cobalt chloride (Fq)w e r e
measured. Calcein encapsulation ratio was calculated by the
equation as follows: encapsulation ratio (%) = [(Fin − Fq ·
r)/(Ft − Fq · r)] · 100, where r is compensation coeﬃcient
(r = 1.04).
2.5. Cell Culture. HepG2 cells, a human hepatocellular
carcinoma cell line, A549 cells, a adenocarcinomic human
alveolar basal epithelial cells, and NIH3T3 cells, a mouse
embryonic ﬁbroblast cell line, were obtained from Riken
Bioresource Center (Tsukuba, Japan). HepG2, A549, and
NIH3T3 cells were grown in DMEM, containing 1×105 U/L
of penicillin, 0.1g/L of streptomycin supplemented with
10% FCS at 37◦C in a humidiﬁed 5% CO2 and 95% air
atmosphere.
2.6. In Vitro Gene Transfer. In vitro transfection of the
pDNA/CyDs/AF-liposomes was performed utilizing the
luciferase expression of pDNA (pRL-CMV-Luc or pGL3-
control vector) in HepG2, A549, and NIH3T3 cells. The
cells (2 × 105 cells per 24 well plate) were seeded 6h
before transfection and then washed twice with 500μLo f
serum-freemedium.TwohundredμLofserum-freemedium
containing pDNA/CyDs/AF-liposomes in the absence and
presence of AF as a competitor protein or BSA as a control
protein were added to each dish and then incubated at
37◦C for 3h. After washing HepG2 cells with serum-free
medium twice, 500μL of medium containing 10% FCS were
added to each dish and then incubated at 37◦Cf o r2 1 h .
After transfection, the gene expression was measured as
follows: Renilla and ﬁreﬂy luciferase contents in the cell
lysate were quantiﬁed by a luminometer (Lumat LB9506,
EG&G Berthold Japan, Tokyo, Japan) using the Promega
Renilla and ﬁreﬂy luciferase assay reagent (Tokyo, Japan),
respectively. It was conﬁrmed that CyDs and AF-liposomes
had no inﬂuence on the luciferase assays under the present
experimental conditions. Total protein content of the super-
natant was determined by Bio-Rad protein assay kit (Bio-
Rad Laboratories, Tokyo, Japan). EGFP-expressing cells were
determined by a confocal laser scanning microscopy (CLSM,
Olympus FV300-BXCarl Zeiss LSM-410, Tokyo, Japan) with
an argon laser at 488nm after ﬁxation. Brieﬂy, the cells
(2 × 105 cells per 35mm glass bottom dish) were seeded
6h before transfection and then washed twice with 500μL
of serum-free medium. Transfection with pEGFP N1 DNA
was performed using the same protocol as described above.
The EGFP expression ratio was determined by the number
of EGFP-expressing cells per 100 cells. To observe the cel-
lular uptake of Rhodamine-labeled AF-liposomes (RH-AF-
liposomes) and Alexa-labeled pDNA (Alexa-pDNA), HepG2
cells (2 × 105 cells/dish) were incubated with the Alexa-
pDNA/CyDs/RH-AF-liposomes for 3h. After incubation,
the cells were rinsed with PBS (pH 7.4) twice and ﬁxed
in methanol at 4◦C for 5min prior to observation by
aC L S M .
2.7. Reverse Transcriptase-Polymerase Chain Reaction (RT-
PCR). Total RNA was isolated using an RNeasy Mini Kit
(Qiagen, Tokyo, Japan) according to manufacturer’s proce-
dure. The synthesis of the ﬁrst-strand cDNA was carried
out with SuperScript III reverse transcriptase (Invitrogen,
Carlsbad, CA). Approximately, 1μM random primer was
annealed to 3μg of total RNA and extended with 1μL
of reverse transcriptase in 10μL of reaction containing
4μLo f5× ﬁrst-strand buﬀer, 1μL of deoxyribonucleotide
triphosphate (dNTPs), and 1μL of dithiothreitol. Reverse
transcription was carried out at 42◦C for 50min. The
expression of mRNA transcripts of Renilla luciferase (for-
ward: 5 -GGCTGACCGCCCAACGACCCCC-3 ,r e v e r s e :5  -
GACGTCAATAGGGGGCGGACTTGG-3 )a n dh u m a nβ-
actin (forward: 5 - TCCTGTGGCATCCATCCACGAAACT-
3 ,r e v e r s e :5  -GAAGCATTTGCGGTGGACGAT-3 )w a s
determined by RT-PCR. PCR ampliﬁcation was carried out
in a PCR Thermal Cycler (Takara Bio, Shiga, Japan). PCR
was conducted in a total volume of 100μLw i t h2μL of the
cDNA solution, 2μLo fe a c h1 0m Md N T P ,2 . 5Uo fT a K a R a
Ex Taq DNA polymerase, and 500nM of both forward and
reverse primers. The thermal cycling conditions were set to
95◦C for 11min, followed by 20cycles of ampliﬁcation at
94◦C for 1min, 55◦C for 1min, and 72◦Cf o r2 m i nf o r
denaturing, annealing, and extension. After the last cycle,
the samples were incubated at 72◦C for 7min. The ampliﬁed
products were separated on 2% agarose gels by electrophore-
sis and visualized with 0.1% ethidium bromide under UV
light.
2.8. Cytotoxicity. The eﬀects of pDNA/CyDs/AF-liposomes
on cell viability were measured as reported previously [27].
The transfection was performed as described in the trans-
fection section. After washing twice with Hanks’ balanced
salt solutions (HBSS, pH 7.4) to remove pDNA and/or
AF-liposomes, 270μL of fresh HBSS and 30μLo fW S T - 1
reagent were added to the plates and incubated at 37◦Cf o r
3 0 m i n .T h ea b s o r b a n c eo ft h es o l u t i o nw a sm e a s u r e da t
450nm,withreferringabsorbanceat655nm,withaBio-Rad
Model 550 microplate reader (Bio-Rad Laboratories, Tokyo,
Japan).
2.9. Membrane Fluidity of Liposomes. To evaluate the ther-
modynamic characterization of liposomes in the pres-
ence of CyDs, diﬀerential scanning calorimetry (DSC)
measurements were performed. Brieﬂy, N-liposome or
DLPC-liposome suspension (5μmol/mL of lipids) and
CyDs (10–50mM) solution were mixed, and the solution
was analyzed by a Microcal MC2 scanning calorimeter
(Northampton, MA) with a scanning rate of 1◦C/min in
the range of 4–70◦C. From the thermographs, membrane
phase-inversion temperature and its enthalpy (ΔHcal) were
calculated.
2.10. Statistical Analysis. Data are given as the mean ± SEM.
Statistical signiﬁcance of means for the studies was deter-
mined by analysis of variance followed by Scheﬀe’s test. P
values for signiﬁcance were set at .05.Journal of Drug Delivery 5
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Figure 3: Gene transfer activity of pDNA/CyDs/AF-liposomes
in HepG2 cells. pDNA was pRL-CMV. The charge ratio of AF-
liposomes/pDNA was 1.6. CyDs were added to AF-liposomes
suspension before freeze-drying. The concentration of CyD was
1μM/μM lipids. Cells were incubated with pDNA/γ-CyDs/AF-
liposomes for 3h in FCS-free medium. After washing twice, the
cells were incubated for 21h in culture medium supplemented with
10% FCS. The luciferase activity in cell lysates was determined
using a luminometer. Each value represents the mean ± SEM of 3–
7 experiments. ∗P<. 05 versus without CyD.
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Figure 4: Eﬀect of γ-CyDs on Renilla luciferase mRNA levels
after transfection of pDNA/AF-liposomes or pDNA/γ-CyDs/AF-
liposomes in HepG2 cells. The charge ratio of AF-liposomes/pDNA
was 1.6. CyDs were added to AF-liposomes suspension before
freeze-drying. The concentration of CyD was 1μM/μM lipids. Cells
were incubated with pDNA/γ-CyDs/AF-liposomes for 3h in FCS-
free medium. After washing twice, the cells were incubated for
21h in culture medium supplemented with 10% FCS. The Renilla
luciferase mRNA level in HepG2 cells was assayed by RT-PCR. The
luciferase mRNA level in each sample was normalized to abundance
of β-actin mRNA. Each value represents the mean ± SEM of 3–7
experiments. ∗P<. 05 versus without CyD.
3. Results
3.1. Interaction between AF-Liposomes and CyDs. CyDs have
been reported to interact with cell membrane constituents
suchascholesterolandphospholipids,resultingintheinduc-
tion of hemolysis of human and rabbit red blood cells at
high concentrations of CyDs [28–30]. In addition, CyDs are
well known to disrupt liposomal membranes, depending on
CyD cavity sizes and membrane components [31, 32]. Then,
we evaluated the interaction of CyDs with AF-liposomes6 Journal of Drug Delivery
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Figure 5: Gene transfer eﬃciency of pDNA/AF-liposomes or
pDNA/γ-CyDs/AF-liposomes in HepG2 cells. pDNA was (a)
pEGFP-N1 or (b) pGL3-control vector. The charge ratio of AF-
liposomes/pDNA was 1.6. γ-CyDs were added to AF-liposomes
suspension before freeze-drying. The concentration of CyDs was
1μM/μM lipids. Cells were incubated with pDNA/γ-CyDs/AF-
liposomes for 3h in FCS-free medium. After washing twice, the
cells were incubated for 21h in culture medium supplemented with
10% FCS. (a) Cells were determined by a confocal laser scanning
microscopy.Thepercentageinparenthesisrepresentsfrequencyrate
of EGFP expression cells. (b) The luciferase activity in cell lysates
was determined using a luminometer. Each value represents the
mean ± SEM of 3–7 experiments. ∗P<. 05 versus without CyD.
by measuring the leakage of calcein, a ﬂuorescent marker,
from calcein-encapsulated AF-liposomes in isotonic Tris-
HCl-buﬀered saline (pH 7.5) (Figure 2). α-CyD and DM-
β-CyD signiﬁcantly increased calcein leakage from calcein-
encapsulated AF-liposomes after incubation for 30min in
a concentration-dependent manner. On the other hand,
calcein leakage in the presence of γ-CyD and three types of
HP-CyDs was low even at the concentration of 20mM CyDs.
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Figure 6: Eﬀects of competitors on gene transfer activity of
pDNA/γ-CyD/N-liposomes and AF-liposomes in HepG2 cells.
pDNAwaspRL-CMV.ThechargeratioofAF-liposomes/pDNAwas
1.6. γ-CyD was added to AF-liposomes suspension before freeze-
drying. The concentration of γ-CyD was 1μM/μM lipids. Cells
were incubated with pDNA/γ-CyDs/AF-liposomes for 3h in FCS-
free medium. After washing twice, the cells were incubated for 21h
in culture medium supplemented with 10% FCS. The luciferase
activity in cell lysates was determined using a luminometer. The
concentrations of AF and BSA were 5mg/mL. Each value represents
the mean ± SEM of 3–7 experiments. ∗P<. 05 versus control.
These results suggest that the interaction of γ-CyD and HP-
CyDs with AF-liposomes was weaker than that of α-CyD and
DM-β-CyD.
3.2. In Vitro Gene Delivery of AF-Liposomes Associated with
CyDs. Next, we evaluated in vitro gene transfer activity of
pDNA/CyDs/AF-liposomes in HepG2 cells, ASGP-R positive
cells (Figure 3). Here, we used pRL-CMV (CMV promoter)
as pDNA and the charge ratio (AF-liposomes/pDNA) of 1.6
optimized by our previous study (data not shown). The gene
transfer activity of pDNA/γ-CyD/AF-liposomes in HepG2
cells was signiﬁcantly higher than that of pDNA/HP-α-,
HP-β-, and HP-γ-CyDs/AF-liposomes (Figure 3). Next, we
measured theRenilla luciferase mRNA level after transfection
of pDNA/CyDs/AF-liposomes in HepG2 cells by the RT-
PCR method (Figure 4). As predicted, γ-CyD signiﬁcantly
increased the luciferase expression, but HP-γ-CyD did not,
suggesting that γ-CyD is involved in the enhancing eﬀect on
luciferase expression at or prior to a transcription process.
To evaluate the enhancing eﬀects of γ-CyD on gene
transferactivityofAF-liposomesassociatingpDNAencoding
EGFP controlled by a CMV or SV40 promoter, we examined
EGFP and ﬁreﬂy luciferase gene expression after transfection
of pDNA/γ-CyDs/AF-liposomes in HepG2 cells (Figure 5).Journal of Drug Delivery 7
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Figure 7: Gene transfer activity of pDNA/CyDs/AF-liposomes in (a) A549 cells and (b) NIH3T3 cells. pDNA was pRL-CMV. The charge
ratio of AF-liposomes/pDNA was 1.6. CyDs were added to AF-liposomes suspension before freeze-drying. The concentrations of γ-CyDs
were 1μM/μM lipids. Cells were incubated with pDNA/γ-CyDs/AF-liposomes for 3h in FCS-free medium. After washing twice, the cells
were incubated for 21h in culture medium supplemented with 10% FCS. The luciferase activity in cell lysates was determined using a
luminometer. Each value represents the mean ± SEM of 3–7 experiments. ∗P<. 05 versus without CyD.
Table 2: ζ-potential value and particle size of pDNA/AF-liposomes
or pDNA/γ-CyDs/AF-liposomes.
CyD Particle size ζ-potential
(nm) (mV)
Without CyD 357.9 ± 17.7 21.5 ± 2.9
γ-CyD 277.9 ± 10.5∗ 17.0 ± 2.7
HP-γ-CyD 348.0 ± 16.5 22.3 ± 3.3
ThechargeratioofAF-liposome/pDNAwas1.6.γ-CyDswereaddedtoAF-
liposome suspension before freeze-drying. The concentrations of γ-CyDs
were 1μM/μM lipids. The ζ-potential was measured by a light-scattering
method. The particle size was determined using a photon correlation
spectroscopic analyzer. Each value represents the mean ± SEM of 3
experiments. ∗P<. 05 versus without CyD.
The extent of EGFP-expressing cells in the pDNA/AF-
liposomes system without CyDs was found to be 8%,
while that with γ-CyD and HP-γ-CyD were 19% and
10%, respectively (Figure 5(a)). Additionally, the enhancing
eﬀect of γ-CyD was observed in the pGL3-control vector
encoding ﬁreﬂy luciferase and having a SV40 promoter
(Figure 5(b)). These results suggest that the enhancing eﬀect
of γ-CyD on gene transfer activity of AF-liposomes is a gene-
and promoter-independent manner. To conﬁrm whether
pDNA/γ-CyD/AF-liposomes have ASGP-R-mediated gene
transfer activity, we performed transfection experiments in
HepG2 cells in the presence and absence of AF, as an ASGP-
Rcompetitiveinhibitor.Here,weconﬁrmedthatASGP-Rare
expressed in HepG2 cells by the RT-PCR method (data not
shown), which is consistent with previous ﬁndings [33–35].
As shown in Figure 6, gene transfer activity of AF-liposomes
was markedly inhibited by the addition of AF, but not BSA, a
control protein. These results suggest that AF-liposomes had
the ASGP-R-mediated gene transfer activity. Interestingly,
the similar enhancing eﬀects of γ-CyD on Renilla luciferase
protein expression after transfection of pDNA/AF-liposomes
were, however, observed in A549 cells and NIH3T3 cells,
ASGP-R negative cells (Figure 7). These results suggest that
γ-CyD enhances the transfection eﬃciency of pDNA/AF-
liposomes in ASGP-R-independent manner.
3.3. Cytotoxicity. To reveal cytotoxicity of pDNA/CyDs/AF-
liposomes, we examined the WST-1 method (Figure 8).
Although the cell viability after treatment with pDNA/AF-
liposomes and pDNA/CyDs/AF-liposomes for 3h slightly
decreased as a charge ratio of AF-liposomes/pDNA was
increased in both HepG2 and NIH3T3 cells, that is,
more than 80% of cell viability after application of
pDNA/CyDs/AF-liposomes was observed at the charge ratio
of 1.6 used in the transfection study as described above.
These results suggest that pDNA/CyDs/AF-liposomes have
great advantages as a nonviral vector, that is, superior trans-
fection eﬃciency and less cytotoxicity, and the enhancing8 Journal of Drug Delivery
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Figure 8: Cytotoxicity of pDNA/AF-liposomes or pDNA/γ-
CyDs/AF-liposomes with various charge ratios in (a) HepG2 and
(b) NIH3T3 cells. The concentrations of γ-CyDs were 1μM/μM
lipids. Cells were incubated with pDNA/γ-CyDs/AF-liposomes for
3h in FCS-free medium. Cell viability was assayed by the WST-1
method. Each point represents the mean ± SEM of 3 experiments.
eﬀect of γ-CyD on gene transfer activity of pDNA/AF-
liposomes is not associated with cytotoxicity.
3.4. Eﬀects of γ-CyD on Physicochemical Properties of
pDNA/AF-Liposomes. To clarify physicochemical properties
of the pDNA/AF-liposomes, we determined the parti-
cle sizes and ζ-potential values of the pDNA/γ-CyD/AF-
liposomes at the charge ratio of 1.6. The mean diameter
of the pDNA/γ-CyD/AF-liposomes was smaller than that
of pDNA/AF-liposomes or pDNA/HP-γ-CyD/AF-liposomes
(Table 2). Meanwhile, the ζ-potential values of pDNA/AF-
liposomes, pDNA/γ-CyD/AF-liposomes, and pDNA/HP-γ-
CyD/AF-liposomes were almost comparable (Table 2). These
results indicate that γ-CyD reduced the particle size of
AF-liposomes but did not change the ζ-potential value of
pDNA/CyD/AF-liposomes.
Table 3: Encapsulation ratios of pDNA and γ-CyDs into AF-
liposomes.
CyD Encapsulation ratio of
pDNA (%)
Encapsulation ratio of
γ-CyDs (%)
Without CyD 42.4 ± 4.3 —
γ-CyD 58.2 ± 1.8∗ 10.2 ± 0.5
HP-γ-CyD 41.9 ± 3.3 11.0 ± 2.2
The charge ratio of AF-liposome/pDNA was 1.6. γ-CyDs were added to AF-
liposome suspension before freeze-drying. The concentrations of γ-CyDs
were 1μM/μM lipids. The encapsulation ratios of pDNA were determined
using Picogreen assay. The encapsulation ratios of γ-CyDs were determined
by an anthrone-sulfuric acid method. Each value represents the mean ±
SEM of 3 experiments. ∗P<. 05 versus without CyD.
Next, we examined the eﬀects of γ-CyDs on encapsu-
lation ratios of pDNA into AF-liposomes (Table 3). The
encapsulationratioofpDNAinpDNA/γ-CyD/AF-liposomes
was signiﬁcantly higher than those of pDNA/HP-γ-CyD/AF-
liposomes and pDNA/AF-liposomes. Meanwhile, the encap-
sulation ratios of γ-CyD and HP-γ-CyD into AF-liposomes
were approximately 10.2% and 11.0%, respectively. These
results suggest that γ-CyD improves the encapsulation of
pDNA into AF-liposomes, although the extent of γ-CyD
encapsulation into AF-liposomes is not high. In addition,
both the encapsulation ratio of pDNA into AF-liposomes
and gene transfer activity of pDNA/AF-liposomes were
raised, as the number of the freeze-thaw cycle was increased,
suggesting that the encapsulation of pDNA in AF-liposomes
is correlated with the gene transfer activity of pDNA/AF-
liposomes (Table 4).
3.5. Eﬀects of γ-CyD on Membrane Fluidity of Liposomes. It
is known that membrane ﬂuidity of liposomes aﬀects the
release proﬁles as well as a retention time of drug encapsu-
lated into liposomes. Therefore, we investigated the eﬀects
of γ-CyD on membrane ﬂuidity of AF-liposomes using a
Microcal MC2 scanning calorimeter. In the present study,
we utilized N-liposomes to eliminate the eﬀects of the heat
degeneration of AF in a DSC thermograph. Figure 9 shows
the eﬀects of γ-CyD and HP-γ-CyD on DSC thermograms of
N-liposomes (5mM of total lipids). The peak derived from
gel-to-ﬂuid state transition in N-liposomes was observed at
55◦C, while new peak was appeared at 42◦C in the presence
of 50mM of γ-CyD (Figure 9(a)). On the other hand,
no signiﬁcant change in DSC thermographs was observed
in the presence of HP-γ-CyD (Figure 9(b)). These results
suggest that γ-CyD may aﬀect the membrane ﬂuidity of N-
liposomes.
Generally, membrane ﬂuidity and phase transition of
liposomes are determined by the intensity of lipid-lipid
interactions such as hydrophobic interaction, van der Waals
forces, and hydrogen bond. Therefore, to evaluate the eﬀects
ofγ-CyDonlipid-lipidinteractionsinAF-liposomes,weper-
formedDSCanalysisofDLPC-liposomesinthepresenceand
absence of γ-CyD. The reason why we used DLPC-liposomes
is due to clear observation of lipid-lipid interaction using
DLPC composed of AF-liposomes. Figure 10 shows theJournal of Drug Delivery 9
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Figure 9: DSC thermograms of the gel-to-ﬂuid state transition of N-liposomes at various concentrations of γ-CyDs. γ-CyDs were added to
N-liposomes suspension. The concentration of total lipids of N-liposomes was 5mM. The experiments were performed in the range of 4◦C
to 70◦C using a Microcal MC2 apparatus. The temperature scanning rate was 1◦C/min.
Table 4: Encapsulation ratio of pDNA into AF-liposomes and gene
transfer activity of pDNA/AF-liposomes at various cycles of freeze-
thaw in HepG2 cells.
Freeze thaw
cycle
Encapsulation ratio of
pDNA (%)
Gene transfer activity
(fold)
0 35.2 ± 0.9 0.56 ± 0.07
1 36.2 ± 0.5 0.59 ± 0.06
2 37.4 ± 2.1 0.76 ± 0.02
3 42.4 ± 4.3 1
5 44.1 ± 1.3 1.03 ± 0.02
The charge ratio of AF-liposomes/pDNA was 1.6. pDNA/AF-liposome was
prepared using a freeze-thaw method which was repeated from 0 to 5 cycles.
Cells were incubated with pDNA/γ-CyDs/AF-liposome for 3h in FCS-free
medium. After washing twice, the cells were incubated for 21h in culture
medium supplemented with 10% FCS. The luciferase activity in cell lysates
was determined using a luminometer. Each value represents the mean ±
SEM of 3 experiments.
eﬀectsofγ-CyDandHP-γ-CyDonDSCthermograms,phase
transition temperature, and enthalpy (ΔHcal) of DLPC-
liposomes (5mM of total lipids). The phase transition
temperature (Tc) of DLPC-liposomes in the presence of γ-
CyD was shifted to high temperature as the concentration
of γ-CyD was increased (Figures 10(a) and 10(c)). The
ΔHcal value of DLPC-liposomes in the γ-CyD system was
d r a s t i c a l l ye l e v a t e da t2 0 m Mo fγ-CyD (Figure 10(d)).
Meanwhile,inthecaseofHP-γ-CyD,therewasnosigniﬁcant
change in DSC thermograms, phase transition temperature,
andthe ΔHcalvalues(Figures10(b),10(c)and 10(d)).Taken
together, these results strongly suggest that γ-CyD enhances
the lipid-lipid interaction of DLPC-liposomes, leading to the
membrane stabilization of DLPC-liposomes.
3.6. Cellular Uptake of pDNA/AF-Liposomes. Next, we exam-
ined the cellular uptake of pDNA/γ-CyD/AF-liposomes into
HepG2 cells using a CLSM. Figure 11 shows the CLSM
images for distribution of RH-AF-liposomes and Alexa-
pDNA in HepG2 cells at 3h after transfection. The strong
ﬂuorescence derived from RH-AF-liposomes and Alexa-
pDNA in the presence of γ-CyD was mainly observed in
cytoplasm of HepG2 cells. Meanwhile, the ﬂuorescence RH-
AF-liposomes and Alexa-pDNA in the absence of CyD and
with HP-γ-CyD was mainly observed on cell surface. Hence,
these results suggestthat pDNA/γ-CyD/AF-liposomes can be
internalized into HepG2 cells to a larger extent, compared to
pDNA/AF-liposomes and pDNA/γ-CyD/AF-liposomes.
4. Discussion
In this study, we clariﬁed that pDNA/γ-CyD/AF-liposomes
have potent hepatocyte-selective gene transfer activity and
negligible cytotoxicity, compared to pDNA/AF-liposomes
and pDNA/HP-CyDs/AF-liposomes.
In cationic liposome-mediated gene transfection, lipid
composition and lipid type are the most important physico-
chemical factors, because they aﬀect not only the interaction
with pDNA but also the aﬃnity to target cells [36, 37].
In the present study, we prepared AF-liposomes with a
lipid composition of TMAG/DOPE/DLPC/DPPE (2/4/3/1,
molar ratio). DOPE is known to enhance the endosomal
escape of pDNA due to its structural change into hexagonal
II form at pH 5-6, an endosomal pH range, resulting in
destabilizing endosomal membranes [38, 39]. TMAG, a
cationic lipid, makes it possible to interact with pDNA in
AF-liposomes. Additionally, DPPE was used as a binding
lipid with AF. Actually, cationic liposomes composed of10 Journal of Drug Delivery
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Figure 10: DSC thermograms (a, b), gel-to-ﬂuid state transition temperature (c), and ΔHcal value (d) of the gel-to-ﬂuid state transition of
DLPC-liposomes at various concentrations of γ-CyDs. γ-CyDs were added to DLPC-liposomes suspension. The DLPC concentration was
5mM. The experiments were performed in the range of 4◦Ct o7 0 ◦C using a Microcal MC2 apparatus. The temperature scanning rate was
1◦C/min. The gel-ﬂuid state transition temperature and ΔHcal were taken at a peak temperature and a peak area of the DSC thermograms,
respectively. Each point represents the mean ± SEM of 3 experiments.
TMAG/DOPE/DLPC (1/2/2, molar ratio) are commercially
available transfection reagents as GeneTransfer, which have
already been utilized in a clinical trial for a nonviral vector
to deliver the interferon-β gene for the treatment of brain
tumor in Japan [40]. Therefore, we used AF-liposomes
composed of these lipids in the present study.
The most important ﬁnding found in the present study
is that γ-CyD enhances transfection eﬃciency of pDNA/AF-
liposomes in HepG2 cells (Figures 3–5) with negligible
cytotoxicity (Figure 8). The enhancing mechanisms of γ-
CyD presumed are discussed as follows.
In the present study, we revealed that transfection eﬃ-
ciency of the pDNA/γ-CyD/AF-liposomes, not N-liposomes,
wasinhibitedbytheadditionofAFinHepG2cells(Figure 6).
Meanwhile, in NIH3T3 cells, transfection eﬃciency of the
pDNA/AF-liposomes was not suppressed by the addition of
AF. These results strongly suggest that pDNA/γ-CyD/AF-
liposomes can be entered HepG2 cells through ASGP-R-
mediated endocytosis, consistent with Aramaki and his
colleague’sreport[41],andtheenhancingeﬀectoftheγ-CyD
may by associated with the ASGP-R-mediated endocytosis.
However, γ-CyD also enhanced gene transfer activity of
pDNA/AF-liposomes even in A549 cells and NIH3T3 cells,
ASGP-R negative cells (Figure 7). These results suggest that
the enhancing eﬀect of γ-CyD on transfection eﬃciency of
pDNA/AF-liposomes is in an ASGP-R-independent manner.Journal of Drug Delivery 11
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Figure 11: Confocal laser microscopic images for distribution of RH-AF-liposomes and Alexa-pDNA in HepG2 cells. Magniﬁcation: ×200.
The charge ratio of AF-liposomes/pDNA was 1.6. γ-CyDs were added to AF-liposomes suspension before freeze-drying. The concentrations
of γ-CyDs were 1μM/μM lipids. Cells were incubated with Alexa-pDNA/γ-CyDs/RH-AF-liposomes for 3h in FCS-free medium. After
washing twice, the cells were observed using a confocal laser scanning microscopy.
The particle sizes and encapsulation ratio of pDNA/γ-
CyD/AF-liposomes should be involved in the enhanc-
ing eﬀect of γ-CyD on gene transfer activity of AF-
liposomes. The particle size of pDNA/γ-CyD/AF-liposomes
was decreased in the presence of γ-CyD, although the ζ-
potential value of pDNA/γ-CyD/AF-liposomes was almost
equivalent to that of pDNA/AF-liposomes and pDNA/HP-γ-
CyD/AF-liposomes (Table 2), suggesting that γ-CyD inhibits
the aggregation of pDNA/AF-liposomes, because the particle
size shows more than 200nm, despite the fact that the
liposomes were extruded through a ﬁlter membrane having
a pore size of 200nm. Meanwhile, the encapsulation ratio
of pDNA was signiﬁcantly increased by adding γ-CyD to
pDNA/AF-liposomes (Table 3). Thus, these lines of evidence
speculate that addition of γ-CyD enhances cellular uptake of
pDNA/AF-liposomes. In fact, the CLSM study demonstrated
that cellular uptake of pDNA/γ-CyD/AF-liposomes was
higher than that of pDNA/γ-CyD/AF-liposomes (Figure 11).
Furthermore, we conﬁrmed that transfection eﬃciency of
pDNA/γ-CyD/AF-liposomes was increased, as the encapsu-
lation ratio of pDNA into pDNA/γ-CyD/AF-liposomes was
augmented (Table 4). In view of the ﬁndings, the particle size
of pDNA/γ-CyD/AF-liposomes and encapsulation ratio of
pDNA into pDNA/γ-CyD/AF-liposomes are crucial role for
enhancing transfection eﬃciency of pDNA/AF-liposomes.
The important question regarding the enhancing eﬀect
of γ-CyD on transfection eﬃciency of pDNA/AF-liposomes
still remains, because three types of HP-CyDs did not have
the enhancing eﬀect. To address this question, the DSC
analysiswasperformed.This studyindicatedthatγ-CyD,but
not HP-γ-CyD, changed membrane ﬂuidity and stabilized
the N-liposomal membranes (Figure 9). In fact, γ-CyD12 Journal of Drug Delivery
increased the Tc value of DLPC-liposomes, although HP-
γ-CyD did not increase anymore (Figure 10). This increase
in the Tc value induced by γ-CyD could be attributed to a
compactness of lipid bilayer of DLPC liposomes. It is thereby
possible that γ-CyD may increase Tc values of the other
liposomes such as DMPC, DPPC, and DSPC. Here, it is well
known that γ-CyD is highly hydrophilic and surface inactive
[17]. Therefore, we presumed that γ-CyD encapsulates the
aqueouscompartmentofliposomesratherthaninthebilayer
of liposomes. Anyhow, it is clear that the magniﬁcation of
the interaction of liposomal membranes containing DLPC
with HP-γ-CyD is weaker than that with γ-CyD, possibly
due to the steric hindrance of the HP group in a HP-γ-CyD
molecule.Takentogether,itislikelythatthestabilizingeﬀects
of γ-CyDonAF-liposomal membranemayleadtoinhibition
of pDNA leakage from AF-liposomes and increase in cellular
uptakeofpDNA,eventuallyleadingtotheenhancementofin
vitro transfection eﬃciency of pDNA/γ-CyD/AF-liposomes
in cells.
Finally, we investigated the role of free γ-CyD on trans-
fection eﬃciency of pDNA/γ-CyD/AF-liposomes in HepG2
cells. The physical mixture of pDNA/AF-liposomes and γ-
CyD in culture medium had no enhancing eﬀect on trans-
fection eﬃciency of pDNA/AF-liposomes (data not shown).
Therefore, encapsulation of γ-CyD into AF-liposomes may
be pivotal for enhancing gene transfer activity. To reveal
the detailed mechanism for the enhancing eﬀect of γ-
CyD associated in AF-liposomes on transfection eﬃciency
of pDNA/AF-liposomes, further elaborate study should be
necessary.
5. Conclusions
In the present study, we demonstrated that γ-CyD enhanced
gene transfer activity of pDNA/AF-liposomes in not only
HepG2cellsbutalsoA549andNIH3T3cells,probablydueto
various eﬀects of γ-CyD on AF-liposomes such as inhibition
ofaggregationoftheliposomes,highencapsulationofpDNA
into the liposomes, and stabilization of lipid bilayer of the
liposomes. Consequently, the potential use of γ-CyD could
be expected as an enhancer of gene transfer activity of AF-
liposomes. Also, these data may be useful for design of cell-
speciﬁc cationic liposomes as a nonviral vector.
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